Fig. 4.
Intratumoral (i.t.) administration of MYXV prolongs survival of BTICs in vivo. Kaplan–Meier survivals of BTIC-bearing mice after treatment with DV or MYXV (5 × 106 FFUs/mouse, single injection) showed MV-treated mice survived longer than DV-treated controls with (A) BT012 (log-rank test, P = .0001), (B) BT025 (log-rank test, P = .0016), and (C) BT048 (log-rank test, P = .0012). Arrows indicate time of viral inoculation.